New smart drug targets Hard-to-Treat ovarian and lung cancers
NCT ID NCT06303505
First seen Jan 11, 2026 · Last updated May 15, 2026 · Updated 17 times
Summary
This study tests a new drug called TUB-040 in people with ovarian cancer that no longer responds to platinum chemotherapy, or with a type of lung cancer that has come back. TUB-040 is an antibody-drug conjugate designed to deliver a cancer-killing agent directly to tumor cells that have a specific marker (NaPi2b). The trial has two phases: first, finding the safest dose, and then comparing doses to see which works best. About 250 participants will receive the drug every three weeks.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OVARIAN CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Arensia Exploratory Medicine
RECRUITINGCluj-Napoca, Romania
Contact Email: •••••@•••••
-
Arensia Exploratory Medicine
RECRUITINGKyiv, Ukraine
Contact Email: •••••@•••••
-
Charité Universitätsmedizin Berlin
RECRUITINGBerlin, 10117, Germany
Contact Email: •••••@•••••
-
Christ Hospital
RECRUITINGCincinnati, Ohio, 45219, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Clínica universidad de Navarra
RECRUITINGMadrid, 28027, Spain
Contact Email: •••••@•••••
-
Guy's Hospital
RECRUITINGLondon, SE1 9RT, United Kingdom
Contact Email: •••••@•••••
-
Mount Sinai
RECRUITINGNew York, New York, 10011, United States
Contact Email: •••••@•••••
-
NEXT Oncology Madrid
RECRUITINGMadrid, 28223, Spain
Contact Email: •••••@•••••
-
Next Oncology Dallas
RECRUITINGIrving, Texas, 75039, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Next Oncology Virginia
RECRUITINGFairfax, Virginia, 22031, United States
Contact Phone: •••-•••-••••
-
OU Health Stephenson Cancer Center
RECRUITINGOklahoma City, Oklahoma, 73104, United States
Contact Email: •••••@•••••
-
Ohio State University
RECRUITINGColumbus, Ohio, 43210#, United States
Contact Email: •••••@•••••
-
The University of Alabama
RECRUITINGBirmingham, Alabama, 35294, United States
Contact Email: •••••@•••••
-
UZ Leuven
RECRUITINGLeuven, 3000, Belgium
Contact Email: •••••@•••••
-
University Hospital Cologne Department of Internal Medicine I
RECRUITINGCologne, 50937, Germany
Contact Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.